Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERizon-Breast: ctDNA-Guided Adaptive Study in HER2+ Metastatic Breast Cancer
NCT07459673Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, pertuzumab in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecanpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07459673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459673.